ORGANOVO HOLDINGS, INC.

VIVS

{{popupValue}}
{{popupSubtitle}}

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
VIVS
CIK0001497253
SIC2836
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupBiological Products, Except Diagnostic Substances

Contact

Address11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO, CA, 92121
Website organovo.com
Phone858-224-1000
CEOKeith Murphy
Employees20

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$144,000.00
Pre-Tax Income$-2.49 million
Net Income$-2.49 million
Net Income to Common$-2.49 million
EPS$-1.70
View All
Balance Sheet
Cash$11.31 million
Assets$14.65 million
Liabilities$4.16 million
Common Equity$10.49 million
Liabilities & Equity$14.65 million
View All
Cash Flow Statement
Calculations
NOPAT$-8.83 million
EBITDA$-2.35 million
Price to EarningsN/A
Price to Book$0.45
ROE-35.31%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

NIO (NIO) Delivers 24,925 Vehicles in June 2025, Up 17.5% Year-Over-Year

NIO Inc. (NYSE:NIO) is one of Goldman Sachs’ top penny stock picks. On July 1, 2025, NIO Inc. shared its latest car delivery numbers. In June, it sold 24,925 vehicles—17.5% more than the same time last year. These included cars from its main NIO brand, the family-friendly ONVO brand, and its smaller high-end brand FIREFLY. […]

Article Link

Is NIO on Track to Meet its 2025 Vehicle Deliveries Target?

NIO delivers more than 114K vehicles in 1H25, up 30% y/y. However, that pace will most likely fall short of its ambitious full-year target.

Article Link

XPeng or NIO: Which Chinese EV Stock Looks Stronger Now?

XPeng's surging deliveries, stronger revenue growth and tech innovation edge put it ahead of rival NIO in China's EV race.

Article Link

VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon “Poster of Distinction” award at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025). The work describes developing a robust, multicellular in vitro model that closely mirrors human intestinal biology, paving the way for safer and more effective therapies for infl

Article Link

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial service to pharma companies, was featured in an oral presentation at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025) showing best-in-class predictive power against a set of test liver compounds. VivoSim’s liver predictive power was shown to be 87.5% for a set of challen

Article Link